Yun Zhong
Stock Analyst at Wedbush
(4.05)
# 693
Out of 5,180 analysts
51
Total ratings
61.11%
Success rate
9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RZLT Rezolute | Upgrades: Outperform | $2 → $5 | $3.05 | +63.93% | 3 | Mar 25, 2026 | |
| IRD Opus Genetics | Maintains: Outperform | $8 → $10 | $4.55 | +119.78% | 2 | Mar 12, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $33 → $35 | $7.25 | +382.76% | 4 | Mar 6, 2026 | |
| MNKD MannKind | Maintains: Outperform | $10 → $8 | $2.45 | +226.53% | 1 | Mar 5, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $240 → $273 | $228.73 | +19.35% | 4 | Feb 12, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $21.76 | +56.25% | 13 | Jan 23, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $11.03 | +45.06% | 3 | Nov 6, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $105.40 | -18.41% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $18.64 | -3.43% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $7.85 | +409.55% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.23 | +435.89% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $3.86 | +107.25% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.41 | +81.41% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.58 | +793.85% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $3.07 | +812.05% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.47 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.46 | +10.65% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $16.35 | +181.35% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.33 | +2,930.30% | 1 | May 5, 2021 |
Rezolute
Mar 25, 2026
Upgrades: Outperform
Price Target: $2 → $5
Current: $3.05
Upside: +63.93%
Opus Genetics
Mar 12, 2026
Maintains: Outperform
Price Target: $8 → $10
Current: $4.55
Upside: +119.78%
Wave Life Sciences
Mar 6, 2026
Maintains: Outperform
Price Target: $33 → $35
Current: $7.25
Upside: +382.76%
MannKind
Mar 5, 2026
Maintains: Outperform
Price Target: $10 → $8
Current: $2.45
Upside: +226.53%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $240 → $273
Current: $228.73
Upside: +19.35%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $21.76
Upside: +56.25%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $11.03
Upside: +45.06%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $105.40
Upside: -18.41%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $18.64
Upside: -3.43%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $7.85
Upside: +409.55%
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $5.23
Upside: +435.89%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $3.86
Upside: +107.25%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.41
Upside: +81.41%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.58
Upside: +793.85%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $3.07
Upside: +812.05%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.47
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.46
Upside: +10.65%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $16.35
Upside: +181.35%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.33
Upside: +2,930.30%